Next Article in Journal
Small Chemical Chromatin Effectors Alter Secondary Metabolite Production in Aspergillus clavatus
Next Article in Special Issue
Cyanobacteria and Cyanotoxins: From Impacts on Aquatic Ecosystems and Human Health to Anticarcinogenic Effects
Previous Article in Journal
Faces of a Changing Climate: Semi-Quantitative Multi-Mycotoxin Analysis of Grain Grown in Exceptional Climatic Conditions in Norway
Previous Article in Special Issue
Immunotoxins: The Role of the Toxin
Toxins 2013, 5(10), 1698-1722; doi:10.3390/toxins5101698
Review

Saporin-S6: A Useful Tool in Cancer Therapy

* ,
,
,
 and
Received: 19 July 2013; in revised form: 17 September 2013 / Accepted: 22 September 2013 / Published: 7 October 2013
(This article belongs to the Special Issue Toxins and Carcinogenesis)
View Full-Text   |   Download PDF [1285 KB, uploaded 7 October 2013]   |   Browse Figures
Abstract: Thirty years ago, the type 1 ribosome-inactivating protein (RIP) saporin-S6 (also known as saporin) was isolated from Saponaria officinalis L. seeds. Since then, the properties and mechanisms of action of saporin-S6 have been well characterized, and it has been widely employed in the construction of conjugates and immunotoxins for different purposes. These immunotoxins have shown many interesting results when used in cancer therapy, particularly in hematological tumors. The high enzymatic activity, stability and resistance to conjugation procedures and blood proteases make saporin-S6 a very useful tool in cancer therapy. High efficacy has been reported in clinical trials with saporin-S6-containing immunotoxins, at dosages that induced only mild and transient side effects, which were mainly fever, myalgias, hepatotoxicity, thrombocytopenia and vascular leak syndrome. Moreover, saporin-S6 triggers multiple cell death pathways, rendering impossible the selection of RIP-resistant mutants. In this review, some aspects of saporin-S6, such as the chemico-physical characteristics, the structural properties, its endocytosis, its intracellular routing and the pathogenetic mechanisms of the cell damage, are reported. In addition, the recent progress and developments of saporin-S6-containing immunotoxins in cancer immunotherapy are summarized, including in vitro and in vivo pre-clinical studies and clinical trials.
Keywords: saporin-S6; saporin; Saponaria officinalis; immunotoxin; immunotherapy; ribosome-inactivating proteins; monoclonal antibodies; rRNA N-glycosylase activity; anti-cancer therapy; hematological tumors saporin-S6; saporin; Saponaria officinalis; immunotoxin; immunotherapy; ribosome-inactivating proteins; monoclonal antibodies; rRNA N-glycosylase activity; anti-cancer therapy; hematological tumors
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Polito, L.; Bortolotti, M.; Mercatelli, D.; Battelli, M.G.; Bolognesi, A. Saporin-S6: A Useful Tool in Cancer Therapy. Toxins 2013, 5, 1698-1722.

AMA Style

Polito L, Bortolotti M, Mercatelli D, Battelli MG, Bolognesi A. Saporin-S6: A Useful Tool in Cancer Therapy. Toxins. 2013; 5(10):1698-1722.

Chicago/Turabian Style

Polito, Letizia; Bortolotti, Massimo; Mercatelli, Daniele; Battelli, Maria G.; Bolognesi, Andrea. 2013. "Saporin-S6: A Useful Tool in Cancer Therapy." Toxins 5, no. 10: 1698-1722.


Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert